Research programme: anti-cancer therapies - Semorex
Latest Information Update: 04 Aug 2016
At a glance
- Originator Semorex
- Class Antineoplastics; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 03 Aug 2016 Preclinical trials in Solid tumours in USA (unspecified route)
- 03 Aug 2016 Preclinical trials in Haematological malignancies in USA (unspecified route)